Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;36(3):147-150.
doi: 10.1097/JXX.0000000000000942.

What the X? Understanding changes in buprenorphine prescribing regulation

Chandra Speight  1
Affiliations

What the X? Understanding changes in buprenorphine prescribing regulation

Chandra Speight. J Am Assoc Nurse Pract. .

Abstract

Opioid use disorder remains an epidemic in the United States. Buprenorphine is a Food and Drug Administration-approved medication for opioid use disorder that is associated with decreased opioid-related mortality and morbidity. Until recently, providers had to have a specialized wavier, a Drug Enforcement Agency (DEA) X, to prescribe buprenorphine for opioid use disorder. The 2023 Consolidated Appropriations Act, signed into law by President Biden, removed X waiver requirements and implements new training requirements for all new and renewing DEA registrants. This brief report outlines the history of buprenorphine prescribing regulation, reviews the recent regulatory changes and their implications for nurse practitioner buprenorphine prescribing, and concludes by considering the importance of promoting buprenorphine access.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The author has no conflicts of interest to disclose.

Similar articles

See all similar articles

Cited by

References

    1. American Association of Nursing Practitioners (AANP). (2022). State practice environment. https://www.aanp.org/advocacy/state/state-practice-environment?gclid=Cjw...
    1. Andraka-Christou B., Capone M. J. (2018). A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. The International Journal of Drug Policy, 54, 9–17. https://doi.org/10.1016/j.drugpo.2017.11.021 - DOI
    1. Andrilla C. H. A., Patterson D. G., Moore T. E., Coulthard C., Larson E. H. (2020). Projected contributions of nurse practitioners and physicians assistant to buprenorphine treatment services for opioid use disorder in rural areas. Medical Care Research and Review, 77(2), 208–216. https://doi.org/10.1177/1077558718793070 - DOI
    1. Andrilla C. H., Moore T. E., Patterson D. G., Larson E. H. (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5‐year update. The Journal of Rural Health, 35(1), 108–112. https://doi.org/10.1111/jrh.12307 - DOI
    1. Centers for Disease Control and Prevention. (November 17, 2021). Drug overdose death in the U.S. top 100,000 annually. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm

MeSH terms

LinkOut - more resources